Barcelona Study Reveals Potential Alzheimer's Therapy
University of Barcelona researchers developed FLAV-27, a first-in-class G9a inhibitor.
FLAV-27 restored cognitive function in Alzheimer's animal models.
Study highlights potential for Alzheimer's treatment.